[MP-202417] Tarlatamab (SCLC)
Last updated 22.07.2026
Project no.:
MP-202417
Report type:
Joint Clinical Assessment, JCA
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Treatment of extensive-stage small cell lung cancer (ESSCLC)
Note:
This Joint Clinical Assessment (JCA) is being conducted in cooperation with the NCPHP (National Centre for Public Health and Pharmacy) Hungary.
The joint clinical assessment will be published on the European Commission’s website: health.ec.europa.eu/publications/joint-clinical-assessment-report-tovorafenib-ojemda_en
Further background information can be found here: European health technology assessment
| Stage | Date |
|---|---|
| Start | 2nd quarter, 2025 |
| voraussichtlicher Abschluss | 3rd quarter, 2026 |